Non-seminomatous Germ-cell Tumors Clinical Trial
Official title:
A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors
Cabazitaxel is a new generation taxane with a high capacity for blood-brain barrier crossing
and limited peripheral neuro-toxicity, two major potential advantages in patients with
advanced NSGCTs.
Cabazitaxel has a broader in vitro spectrum of activity than docetaxel. Taxanes have
demonstrated activity in pre-treated GCTs and are now part of standard treatment, but
cabazitaxel has not yet been tested in patients with NSGCT.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment